NZ746680A - Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same - Google Patents

Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same

Info

Publication number
NZ746680A
NZ746680A NZ746680A NZ74668015A NZ746680A NZ 746680 A NZ746680 A NZ 746680A NZ 746680 A NZ746680 A NZ 746680A NZ 74668015 A NZ74668015 A NZ 74668015A NZ 746680 A NZ746680 A NZ 746680A
Authority
NZ
New Zealand
Prior art keywords
ada2
methods
adenosine deaminase
compositions
variants
Prior art date
Application number
NZ746680A
Other languages
English (en)
Inventor
Christopher Thanos
Lin Wang
Michael Shepard
Original Assignee
Halozyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halozyme Inc filed Critical Halozyme Inc
Publication of NZ746680A publication Critical patent/NZ746680A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ746680A 2014-10-14 2015-10-14 Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same NZ746680A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462063936P 2014-10-14 2014-10-14
NZ730563A NZ730563A (en) 2014-10-14 2015-10-14 Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same

Publications (1)

Publication Number Publication Date
NZ746680A true NZ746680A (en) 2020-07-31

Family

ID=54601993

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ746680A NZ746680A (en) 2014-10-14 2015-10-14 Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
NZ730563A NZ730563A (en) 2014-10-14 2015-10-14 Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ730563A NZ730563A (en) 2014-10-14 2015-10-14 Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same

Country Status (16)

Country Link
US (3) US9969998B2 (enExample)
EP (1) EP3207130B1 (enExample)
JP (1) JP6625627B2 (enExample)
KR (1) KR102122463B1 (enExample)
CN (1) CN108064282A (enExample)
AU (2) AU2015332533B2 (enExample)
BR (1) BR112017007765B1 (enExample)
CA (3) CA3203273A1 (enExample)
DK (1) DK3207130T3 (enExample)
EA (1) EA201700181A1 (enExample)
ES (1) ES2753391T3 (enExample)
IL (1) IL251527B (enExample)
NZ (2) NZ746680A (enExample)
PL (1) PL3207130T3 (enExample)
SG (1) SG11201702934TA (enExample)
WO (1) WO2016061286A2 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
DK3186281T3 (da) 2014-08-28 2019-06-11 Halozyme Inc Kombinationsterapi med et hyaluronan-nedbrydende enzym og en immun-checkpoint-inhibitor
JP6625627B2 (ja) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
WO2016191283A2 (en) * 2015-05-22 2016-12-01 University Of Houston System Enzymatic immunomodulation of solid tumors and user thereof
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017156483A1 (en) * 2016-03-11 2017-09-14 University Of Louisville Research Foundation, Inc. Methods and compositions for treating tumors
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN109477103A (zh) * 2016-06-22 2019-03-15 ProQR治疗上市公司Ⅱ 单链rna-编辑寡核苷酸
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP7130630B2 (ja) 2016-09-30 2022-09-05 モレキュラー デバイシーズ， エルエルシー 最適候補化合物を検出するためのコンピュータ装置およびその方法
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
JP2020513248A (ja) 2016-10-19 2020-05-14 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響による親和性細胞抽出
US20180271939A1 (en) * 2017-03-24 2018-09-27 Milton J. Silverman, JR. Genetic method to kill cancer cells by suffocation
WO2018218137A1 (en) 2017-05-25 2018-11-29 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
JP7224650B2 (ja) * 2017-06-21 2023-02-20 エクスエル‐プロテイン ゲーエムベーハー タンパク質薬物とｐ／ａペプチドとのコンジュゲート
US10391154B2 (en) * 2017-07-19 2019-08-27 Leadiant Biosciences Ltd. Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
WO2019040367A1 (en) * 2017-08-19 2019-02-28 Ohio State Innovation Foundation NEW CANCER IMAGING AGENTS BASED ON PEPTIDES
CN111556757A (zh) 2017-10-31 2020-08-18 西方溶瘤细胞有限公司 用于全身递送的平台溶瘤载体
US20200355694A1 (en) * 2017-11-20 2020-11-12 Konica Minolta, Inc. Drug Evaluation Method
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
KR20200104333A (ko) 2017-12-28 2020-09-03 난징 레전드 바이오테크 씨오., 엘티디. Tigit에 대한 단일-도메인 항체 및 이의 변이체
TW201930349A (zh) * 2018-01-08 2019-08-01 大陸商南京傳奇生物科技有限公司 多重特異性抗原結合蛋白及其使用方法
TWI802633B (zh) 2018-01-15 2023-05-21 大陸商南京傳奇生物科技有限公司 針對pd-1之單域抗體及其變異體
AU2018410849B2 (en) 2018-02-27 2025-02-27 Leidos, Inc. PD-1 peptide inhibitors
WO2019166701A1 (en) * 2018-03-02 2019-09-06 Turun Yliopisto Anti-adenosine signaling pathway antibodies conjugated or fused with adenosine deaminase or capable of binding adenosine deaminase
US12133884B2 (en) 2018-05-11 2024-11-05 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
CN120775065A (zh) 2018-07-09 2025-10-14 普瑞赛格恩公司 融合构建体及其使用方法
EP3820520A4 (en) * 2018-07-12 2022-05-11 Corvus Pharmaceuticals, Inc. METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY
CN118755703A (zh) 2018-07-25 2024-10-11 阿特根公司 新型透明质酸水解酶突变体和包含其的药物组合物
WO2020023841A1 (en) * 2018-07-27 2020-01-30 Massachusetts Institute Of Technology Oligomerized protein-polymer conjugates
US12454694B2 (en) 2018-09-07 2025-10-28 Beam Therapeutics Inc. Compositions and methods for improving base editing
CA3128878A1 (en) * 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
CN114096666B (zh) 2019-02-13 2025-03-18 比姆医疗股份有限公司 治疗血红素病变的组合物和方法
JP7586601B2 (ja) * 2019-02-13 2024-11-19 ビーム セラピューティクス インク． 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法
WO2020169577A1 (en) * 2019-02-19 2020-08-27 Medizinische Universität Wien New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
CN109988816A (zh) * 2019-04-12 2019-07-09 浙江夸克生物科技有限公司 一种腺苷脱氨酶测定试剂盒
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
CN110063970B (zh) * 2019-04-30 2024-09-03 上海心脉途医疗科技有限公司 与irAE相关的肠道菌群及irAE的治疗和预防方法
AU2020278864A1 (en) * 2019-05-22 2021-12-23 Toolgen Incorporated Single base substitution protein, and composition comprising same
JP7606471B2 (ja) 2019-05-22 2024-12-25 レイドス， インコーポレイテッド Ｌａｇ３結合ペプチド
CA3153624A1 (en) * 2019-09-09 2021-03-18 Beam Therapeutics Inc. Nucleobase editors and methods of using same
CN110607348B (zh) * 2019-10-14 2023-03-10 中国医学科学院北京协和医院 应用试剂盒和全自动生化仪同时检测两种亚型腺苷脱氨酶同工酶的方法
JP7502861B2 (ja) * 2019-12-27 2024-06-19 旭化成株式会社 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法
EP4161952A1 (en) 2020-06-04 2023-04-12 Leidos, Inc. Immunomodulatory compounds
WO2022011256A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
US11578102B2 (en) 2020-07-31 2023-02-14 Leidos, Inc. LAG3 binding peptides
CN120738156A (zh) 2020-08-07 2025-10-03 阿特根公司 制备重组玻尿酸酶的方法
US11987646B2 (en) 2020-10-12 2024-05-21 Leidos, Inc. Immunomodulatory peptides
WO2022087484A1 (en) * 2020-10-23 2022-04-28 Williams Katherine L Antibodies to coronavirus sars-cov-2
EP4247410A4 (en) 2020-11-19 2025-05-07 KaliVir Immunotherapeutics, Inc. ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICROENVIRONMENT REMOVAL
CN114350691B (zh) * 2021-03-05 2023-12-08 华熙生物科技股份有限公司 一种高效表达透明质酸水解酶的基因及其表达方法
CN113416735B (zh) * 2021-03-17 2023-01-31 云南中烟工业有限责任公司 一种烟草生殖细胞特异高表达基因及应用
JP2024511163A (ja) * 2021-03-26 2024-03-12 ビーム セラピューティクス インク． アデノシンデアミナーゼバリアント及びその使用
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
CN113533279B (zh) * 2021-07-15 2022-07-29 河北农业大学 一种利用荧光二肽纳米微球/核酸适配体检测恩诺沙星的方法
US20240350546A1 (en) * 2021-08-31 2024-10-24 The Texas A&M University System Chimeric antigen receptor (car) t cell therapy platform
JP2023063852A (ja) * 2021-10-25 2023-05-10 株式会社タムロン 検査装置および情報処理システム
US20250295694A1 (en) * 2021-11-12 2025-09-25 Georgia Tech Research Corporation Adenosine deaminase 2 compositions and methods for using same
CN114965293B (zh) * 2022-05-10 2025-05-09 北京理工大学重庆创新中心 偏振光谱特征融合的水中氨氮检测方法
WO2023249408A1 (ko) * 2022-06-22 2023-12-28 (주)알테오젠 N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
CN114935572A (zh) * 2022-07-25 2022-08-23 香港科技大学深圳研究院 一种基于纳米材料的可视化尿酸检测方法

Family Cites Families (266)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2488564A (en) 1947-06-03 1949-11-22 Orthe Pharmaecutlcal Corp Preparation of hyaluronidase
US2488565A (en) 1947-06-04 1949-11-22 Ortho Pharma Corp Preparation of hyaluronidase
US2676139A (en) 1950-09-01 1954-04-20 American Home Prod Hyaluronidase
US2808362A (en) 1952-05-02 1957-10-01 Armour & Co Preparation of hyaluronidase
US2795529A (en) 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
US2806815A (en) 1955-04-12 1957-09-17 Ortho Pharma Corp Stabilized hyaluronidase
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3847770A (en) 1972-04-10 1974-11-12 Continental Can Co Photopolymerizable compositions prepared from beta hydroxy esters and polyitaconates
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
GB8322007D0 (en) 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
EP0461200B1 (en) 1989-02-21 1997-01-22 Washington University Modified forms of reproductive hormones
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
HU218893B (hu) 1994-03-31 2000-12-28 Amgen Inc. A megakariocita szaporodás és differenciálódás stimulálására szolgáló módszerek és vízoldható készítmények
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US20020159979A1 (en) 1994-06-06 2002-10-31 Children's Hospital, Inc. Adeno-associated virus materials and methods
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
FR2735789B1 (fr) 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
CA2230758A1 (en) 1995-09-08 1997-03-13 Genzyme Corporation Improved aav vectors for gene therapy
US7001765B2 (en) 1996-03-06 2006-02-21 Medigene Ag Adeno-associated virus vector for boosting immunogenicity of cells
US5747322A (en) 1996-05-09 1998-05-05 The Regents Of The University Of California Recombinant crab collagenase
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
JP2001511648A (ja) * 1997-02-06 2001-08-14 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 樹状細胞由来成長因子
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
WO1999009139A1 (en) 1997-08-15 1999-02-25 Rubicon Laboratory, Inc. Retrovirus and viral vectors
CA2304168A1 (en) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Methods and cell line useful for production of recombinant adeno-associated viruses
US20050158273A1 (en) 1997-09-25 2005-07-21 Harris J. M. Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
JP4465109B2 (ja) 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
ES2222689T3 (es) 1998-03-12 2005-02-01 Nektar Therapeutics Al, Corporation Derivados del polietilenglicol con grupos reactivos proximales.
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6251382B1 (en) 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6824766B2 (en) 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
AU5039399A (en) 1998-07-03 2000-01-24 Neles Field Controls Oy Method and arrangement for measuring fluid
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6491907B1 (en) 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CA2356215C (en) 1998-12-23 2015-11-24 Pfizer Inc. Human monoclonal antibodies to ctla-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
DE19933288A1 (de) 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US6723316B2 (en) 1999-12-22 2004-04-20 Onyx Pharmaceuticals, Inc. Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
DK1259562T3 (da) 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US7223593B2 (en) 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
JP2003533537A (ja) 2000-05-16 2003-11-11 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
DE60144439D1 (de) 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US20020096037A1 (en) 2001-01-25 2002-07-25 Richard Muller Color-coded melody text and method of teaching
US6888319B2 (en) 2001-03-01 2005-05-03 Palomar Medical Technologies, Inc. Flashlamp drive circuit
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
US6653103B2 (en) 2001-03-30 2003-11-25 Wisconsin Alumni Research Foundation Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
US20040106794A1 (en) 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
ATE500808T1 (de) 2001-05-11 2011-03-15 Wellstat Biologics Corp Onkolytische virustherapie
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
WO2003005964A2 (en) 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP4758608B2 (ja) 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
EP1487879B1 (en) 2002-03-01 2012-12-26 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
CN101143221A (zh) 2002-03-15 2008-03-19 布赖汉姆妇女医院 适合治疗剂全身性递送的中央气道给药
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
US20030225260A1 (en) 2002-04-30 2003-12-04 Snyder Richard O. Production of recombinant AAV virions
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP2266601A1 (en) 2002-06-21 2010-12-29 Wellstat Biologics Corporation Administration of therapeutic viruses
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
AU2003268505A1 (en) 2002-09-09 2004-03-29 University Of Tennessee Research Foundation Recombinatant mutants of rhabdovirus and methods of use thereof
WO2004022629A2 (en) 2002-09-09 2004-03-18 Nektar Therapeutics Al, Corporation Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
NZ521851A (en) 2002-10-08 2005-02-25 Auckland Uniservices Ltd Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
EP2572732A1 (en) 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
EP2319857A3 (en) 2003-03-04 2012-06-27 Yeda Research And Development Co., Ltd. Pon polypeptides, polynucleotides encoding same and compositions and methods utilizing same
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
CN1788088B (zh) 2003-03-27 2012-09-26 渥太华健康研究学会 突变的水泡性口炎病毒及其用途
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
WO2005000099A2 (en) * 2003-06-09 2005-01-06 Genzyme Corporation BLOOD FACTOR DOMAINS (BFDs)
WO2005016974A1 (en) 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
ES2874298T3 (es) 2003-09-30 2021-11-04 Univ Pennsylvania Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
WO2005049846A2 (en) 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
ATE554107T1 (de) 2003-12-19 2012-05-15 Genentech Inc Als therapeutika geeignete monovalente antikörperfragmente
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
PT1706424E (pt) 2004-01-12 2009-10-01 Applied Molecular Evolution Variantes da região fc
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005118799A1 (en) 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Ovine hyaluronidase
WO2005116224A2 (en) 2004-05-18 2005-12-08 Children's Memorial Hospital Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP2940043A1 (en) 2004-07-15 2015-11-04 Xencor, Inc. Optimized fc variants
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
WO2006101692A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
US20070020238A1 (en) 2005-06-01 2007-01-25 David Baltimore Method of targeted gene delivery using viral vectors
CN105483093A (zh) 2005-06-23 2016-04-13 休斯顿大学 Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
EP1924596A4 (en) 2005-08-12 2009-07-29 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US7301003B2 (en) 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7601798B2 (en) 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US7989554B2 (en) 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
KR20090019770A (ko) 2006-03-13 2009-02-25 티아이알 테크놀로지 엘피 고상 조명 시스템용 적응형 제어 장치 및 전압 결정 방법
WO2007149686A2 (en) 2006-06-21 2007-12-27 Enzon Pharmaceuticals, Inc. Stabilized proteins
KR20090064453A (ko) 2006-09-14 2009-06-18 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
CN101534861B (zh) 2006-09-15 2013-10-02 安佐制药股份有限公司 具有基于位阻酯的生物可降解连接基的聚环氧烷
US20100178684A1 (en) 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
JP5442452B2 (ja) 2007-02-16 2014-03-12 ウイルツ・バイオロジクス・リミテッド 単純ヘルペスウイルスおよびウイルス複製法
DK2147122T3 (da) 2007-04-20 2014-10-13 Sigma Tau Rare Diseases S A Enzymatisk kræftbehandling
AU2008242748B2 (en) * 2007-04-20 2013-12-05 Unikeris Limited Stable recombinant adenosine deaminase
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
PL2173890T3 (pl) 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
WO2009023270A2 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009111066A1 (en) 2008-03-06 2009-09-11 Halozyme, Inc. Large-scale production of soluble hyaluronidase
US8313896B2 (en) 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
EP2307033A4 (en) 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
CN102165489B (zh) 2008-09-16 2015-11-25 赫斯托克斯公司 生物标志物表达的可再现量化
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
NZ593641A (en) 2008-12-09 2013-01-25 Halozyme Inc Extended soluble ph20 polypeptides and uses thereof
WO2010080909A1 (en) 2009-01-08 2010-07-15 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20120134977A1 (en) 2009-06-01 2012-05-31 Yeda Research And Development Co. Ltd. Prodrugs containing albumin binding probe
CN102481331B (zh) 2009-06-08 2017-09-22 阿穆尼克斯运营公司 葡萄糖调节多肽及其制备和使用方法
CA2764105A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
ME02964B (me) 2009-12-06 2018-07-20 Himerni i hibridni polipeptidi faktora viii-fc, i postupci za njihovu upotrebu
SI2591006T1 (sl) 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
AU2012290121B2 (en) 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
BR112014008849A2 (pt) 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
CA2857398A1 (en) 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
PT3130347T (pt) 2011-12-30 2019-12-10 Halozyme Inc Variantes de polipéptidos de ph20, suas formulações e utilizações
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
CA2876730A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody
EP2997134B1 (en) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
JP6307163B2 (ja) 2013-08-30 2018-04-04 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
US11028143B2 (en) 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
JP6625627B2 (ja) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−２（ａｄａ２）、その変異体の組成物およびそれを使用する方法

Also Published As

Publication number Publication date
US11584923B2 (en) 2023-02-21
CA3203273A1 (en) 2016-04-21
BR112017007765A2 (pt) 2018-01-16
US20230203470A1 (en) 2023-06-29
JP6625627B2 (ja) 2019-12-25
WO2016061286A3 (en) 2016-07-07
US9969998B2 (en) 2018-05-15
AU2018236742B2 (en) 2019-11-21
EP3207130A2 (en) 2017-08-23
IL251527B (en) 2020-07-30
JP2017532045A (ja) 2017-11-02
KR20170065032A (ko) 2017-06-12
WO2016061286A9 (en) 2016-08-25
DK3207130T3 (da) 2019-11-11
AU2015332533B2 (en) 2018-08-30
BR112017007765B1 (pt) 2023-10-03
CN108064282A (zh) 2018-05-22
CA3126536C (en) 2023-07-25
SG11201702934TA (en) 2017-05-30
PL3207130T3 (pl) 2020-02-28
US20160272960A1 (en) 2016-09-22
US20170166878A9 (en) 2017-06-15
EA201700181A1 (ru) 2017-09-29
IL251527A0 (en) 2017-05-29
CA2964317A1 (en) 2016-04-21
WO2016061286A2 (en) 2016-04-21
CA3126536A1 (en) 2016-04-21
CA2964317C (en) 2021-10-05
AU2015332533A1 (en) 2017-04-27
AU2018236742A1 (en) 2018-10-18
ES2753391T3 (es) 2020-04-08
NZ730563A (en) 2019-05-31
EP3207130B1 (en) 2019-08-07
US20180216095A1 (en) 2018-08-02
KR102122463B1 (ko) 2020-06-15

Similar Documents

Publication Publication Date Title
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
NZ752526A (en) Pyrrolobenzodiazepine conjugates
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
WO2017030823A3 (en) Anti-tigit antibodies
PH12016501411B1 (en) Bifunctional cytotoxic agents
WO2017214170A3 (en) Baff-r antibodies and uses thereof
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
EP4339287A3 (en) Modified cells and methods of therapy
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
WO2015164392A8 (en) Novel anti-rnf43 antibodies and methods of use
EP4183806A3 (en) Glycan-interacting compounds and methods of use
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
PH12017500156A1 (en) Angiopoietin-like 4 antibodies and methods of use
WO2015159155A3 (en) Novel ademetionine formulations
MX2019008773A (es) Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos.
WO2016130581A3 (en) Combination cancer therapy
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2022 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20210922

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2023 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20220928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2024 BY COMPUTER PACKAGES INC

Effective date: 20231217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2025 BY COMPUTER PACKAGES INC

Effective date: 20250330

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2026 BY COMPUTER PACKAGES INC

Effective date: 20250917